DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. Glossop, J. R., Nixon, N. B., Emes, R. D., Sim, J., Packham, J. C., Mattey, D. L., Farrell, W. E., & Fryer, A. A. Epigenomics, 9(4):419–428, April, 2017. doi abstract bibtex AIM: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). PATIENTS & METHODS: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria. RESULTS: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85). CONCLUSION: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA.
@article{glossop_dna_2017,
title = {{DNA} methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis},
volume = {9},
issn = {1750-192X},
doi = {10.2217/epi-2016-0042},
abstract = {AIM: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA).
PATIENTS \& METHODS: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria.
RESULTS: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75\%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0\% sensitivity, 90.9\% specificity, AUC 0.85).
CONCLUSION: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA.},
language = {eng},
number = {4},
journal = {Epigenomics},
author = {Glossop, John R. and Nixon, Nicola B. and Emes, Richard D. and Sim, Julius and Packham, Jon C. and Mattey, Derek L. and Farrell, William E. and Fryer, Anthony A.},
month = apr,
year = {2017},
pmid = {27885849},
keywords = {DNA Methylation, Illumina 450K array, T-lymphocyte, disease activity score with 28 joint counts (DAS28), disease-modifying antirheumatic drugs (DMARDs), early rheumatoid arthritis, treatment response},
pages = {419--428},
}
Downloads: 0
{"_id":"LZoxrRMoeseA3PdiE","bibbaseid":"glossop-nixon-emes-sim-packham-mattey-farrell-fryer-dnamethylationatdiagnosisisassociatedwithresponsetodiseasemodifyingdrugsinearlyrheumatoidarthritis-2017","author_short":["Glossop, J. R.","Nixon, N. B.","Emes, R. D.","Sim, J.","Packham, J. C.","Mattey, D. L.","Farrell, W. E.","Fryer, A. A."],"bibdata":{"bibtype":"article","type":"article","title":"DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis","volume":"9","issn":"1750-192X","doi":"10.2217/epi-2016-0042","abstract":"AIM: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). PATIENTS & METHODS: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria. RESULTS: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85). CONCLUSION: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA.","language":"eng","number":"4","journal":"Epigenomics","author":[{"propositions":[],"lastnames":["Glossop"],"firstnames":["John","R."],"suffixes":[]},{"propositions":[],"lastnames":["Nixon"],"firstnames":["Nicola","B."],"suffixes":[]},{"propositions":[],"lastnames":["Emes"],"firstnames":["Richard","D."],"suffixes":[]},{"propositions":[],"lastnames":["Sim"],"firstnames":["Julius"],"suffixes":[]},{"propositions":[],"lastnames":["Packham"],"firstnames":["Jon","C."],"suffixes":[]},{"propositions":[],"lastnames":["Mattey"],"firstnames":["Derek","L."],"suffixes":[]},{"propositions":[],"lastnames":["Farrell"],"firstnames":["William","E."],"suffixes":[]},{"propositions":[],"lastnames":["Fryer"],"firstnames":["Anthony","A."],"suffixes":[]}],"month":"April","year":"2017","pmid":"27885849","keywords":"DNA Methylation, Illumina 450K array, T-lymphocyte, disease activity score with 28 joint counts (DAS28), disease-modifying antirheumatic drugs (DMARDs), early rheumatoid arthritis, treatment response","pages":"419–428","bibtex":"@article{glossop_dna_2017,\n\ttitle = {{DNA} methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis},\n\tvolume = {9},\n\tissn = {1750-192X},\n\tdoi = {10.2217/epi-2016-0042},\n\tabstract = {AIM: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA).\nPATIENTS \\& METHODS: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria.\nRESULTS: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75\\%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0\\% sensitivity, 90.9\\% specificity, AUC 0.85).\nCONCLUSION: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA.},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {Epigenomics},\n\tauthor = {Glossop, John R. and Nixon, Nicola B. and Emes, Richard D. and Sim, Julius and Packham, Jon C. and Mattey, Derek L. and Farrell, William E. and Fryer, Anthony A.},\n\tmonth = apr,\n\tyear = {2017},\n\tpmid = {27885849},\n\tkeywords = {DNA Methylation, Illumina 450K array, T-lymphocyte, disease activity score with 28 joint counts (DAS28), disease-modifying antirheumatic drugs (DMARDs), early rheumatoid arthritis, treatment response},\n\tpages = {419--428},\n}\n\n","author_short":["Glossop, J. R.","Nixon, N. B.","Emes, R. D.","Sim, J.","Packham, J. C.","Mattey, D. L.","Farrell, W. E.","Fryer, A. A."],"key":"glossop_dna_2017","id":"glossop_dna_2017","bibbaseid":"glossop-nixon-emes-sim-packham-mattey-farrell-fryer-dnamethylationatdiagnosisisassociatedwithresponsetodiseasemodifyingdrugsinearlyrheumatoidarthritis-2017","role":"author","urls":{},"keyword":["DNA Methylation","Illumina 450K array","T-lymphocyte","disease activity score with 28 joint counts (DAS28)","disease-modifying antirheumatic drugs (DMARDs)","early rheumatoid arthritis","treatment response"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/tplas","dataSources":["YLgywGcXWx96vKKaB"],"keywords":["dna methylation","illumina 450k array","t-lymphocyte","disease activity score with 28 joint counts (das28)","disease-modifying antirheumatic drugs (dmards)","early rheumatoid arthritis","treatment response"],"search_terms":["dna","methylation","diagnosis","associated","response","disease","modifying","drugs","early","rheumatoid","arthritis","glossop","nixon","emes","sim","packham","mattey","farrell","fryer"],"title":"DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis","year":2017}